You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 9, September 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (35)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in this journal
 Topic Collections
 •Depression
 •Psychiatry, Other
 •Genetics
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls

Alexander Neumeister, MD; Xian-Zhang Hu, MD; David A. Luckenbaugh, MA; Markus Schwarz, MD; Allison C. Nugent, PhD; Omer Bonne, MD; Peter Herscovitch, MD; David Goldman, MD; Wayne C. Drevets, MD; Dennis S. Charney, MD

Arch Gen Psychiatry. 2006;63:978-986.

Context  Tryptophan depletion (TD) is a model used to study the contribution of reduced serotonin transmission to the pathogenesis of major depressive disorder (MDD). Recent studies have not sufficiently addressed the relative contribution of a functional-length triallelic polymorphism in the promoter of the serotonin transporter, 5-HTTLPR, to the behavioral and neural responses to TD in individuals with remitted MDD (rMDD) and controls.

Objective  To determine the role of 5-HTTLPR on the behavioral and neural responses to TD in medication-free patients with rMDD and individually matched controls.

Design  Participants were stratified according to diagnosis and 5-HTTLPR genotypes and underwent TD on one test day and sham depletion on the other test day in a prospective, double-blind, randomized order.

Setting  Outpatient clinic.

Participants  Twenty-seven medication-free patients with rMDD (18 women and 9 men) and 26 controls (17 women and 9 men).

Interventions  Tryptophan depletion was induced by administration of capsules containing an amino acid mixture without tryptophan. Sham depletion used identical capsules containing lactose. Fludeoxyglucose F 18 positron emission tomography was performed 6 hours after TD. Magnetic resonance images were obtained for each participant.

Main Outcome Measures  Quantitative positron emission tomography of regional cerebral metabolic rates for glucose and measures of depression using the Hamilton Depression Rating Scale.

Results  Behavioral responses to TD are affected by 5-HTTLPR in patients with rMDD and controls. A direct effect of 5-HTTLPR on the regulation of regional cerebral metabolic rates for glucose was identified in patients with rMDD for the amygdala, hippocampus, and subgenual anterior cingulate cortex.

Conclusions  Variations in 5-HTTLPR modulate the sensitivity of patients with rMDD and controls to the behavioral effects of TD. In patients with rMDD, variations in triallelic 5-HTTLPR have a direct effect on regulation of regional cerebral metabolic rates for glucose in a corticolimbic circuit that has been implicated in rMDD.


Author Affiliations: Department of Psychiatry, Yale University School of Medicine, West Haven, Conn (Dr Neumeister); Mood and Anxiety Disorders Program, Sections on Experimental Therapeutics and Pathophysiology (Drs Neumeister and Charney) and Neuroimaging in Mood and Anxiety Disorders (Drs Nugent, Bonne, and Drevets and Mr Luckenbaugh), National Institute of Mental Health, Bethesda, Md; Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Bethesda (Drs Hu and Goldman); Department of Neurochemistry, University Hospital of Psychiatry, Munich, Germany (Dr Schwarz); PET Department, Clinical Center, National Institutes of Health, Bethesda (Dr Herscovitch); and Department of Psychiatry, Mount Sinai School of Medicine, New York, NY (Dr Charney).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED LETTER

Affective Temperament: A Mediating Variable Between Environment and Clinical Depression?
Zoltan Rihmer, Xenia Gonda, Kareen K. Akiskal, and Hagop S. Akiskal
Arch Gen Psychiatry. 2007;64(9):1096-1097.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of a single dose of citalopram on amygdala response to emotional faces
Murphy et al.
Br. J. Psychiatry 2009;194:535-540.
ABSTRACT | FULL TEXT  

Neurobiological mechanisms in major depressive disorder
aan het Rot et al.
CMAJ 2009;180:305-313.
FULL TEXT  

Mood changes after delivery: role of the serotonin transporter gene
Sanjuan et al.
Br. J. Psychiatry 2008;193:383-388.
ABSTRACT | FULL TEXT  

Neural Response to Catecholamine Depletion in Unmedicated Subjects With Major Depressive Disorder in Remission and Healthy Subjects
Hasler et al.
Arch Gen Psychiatry 2008;65:521-531.
ABSTRACT | FULL TEXT  

Serotonin Transporter Gene Polymorphism (5-HTTLPR) and Anxiety Reactivity in Daily Life: A Daily Process Approach to Gene-Environment Interaction
Gunthert et al.
Psychosom. Med. 2007;69:762-768.
ABSTRACT | FULL TEXT  

Affective Temperament: A Mediating Variable Between Environment and Clinical Depression?
Rihmer et al.
Arch Gen Psychiatry 2007;64:1096-1097.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.